drugset / Trial / NCT01655212

Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial

NCT01655212

RandomizedParallel-groupSingle-blindTreatment

Summary

The objective of the trial is to investigate whether early treatment with oral valganciclovir of infants with both congenital cytomegalovirus infection and sensorineural hearing loss can prevent progression of hearing loss.

Timeline

Start
2012-06
Primary completion
2013-10
Completion
2013-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Valganciclovir Small molecule 16 mg/kg Oral